Trial Profile
Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 27 Mar 2019 Status changed from active, no longer recruiting to completed.
- 10 Jan 2019 Planned End Date changed from 1 Mar 2018 to 5 Mar 2019.
- 11 Dec 2012 Planned end date changed from 1 Aug 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov.